MXCT
MaxCyte, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$1.28
+1.59%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
Market Cap
$132.10M
MomentumView details →
1D Return
+1.59%
YTD Return
−18.39%
RSI (14)
50.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
Market Cap
$132.10M
RSI (14)
50.4
MomentumView details →
1D Return
+1.59%
YTD Return
−18.39%
SummaryUpdated Jun 1, 2026
MaxCyte, Inc. (NASDAQ:MXCT) is a global life sciences company founded in 1998 and headquartered in Rockville, Maryland. The company specializes in cell engineering technology that enables the development of next-generation cell therapies. MaxCyte went public in July 2021 and has established itself as a key enabler in the emerging cell and gene therapy industry. The company's electroporation technology platform has supported the development of CASGEVY, the first FDA-approved non-viral cell therapy, and maintains partnerships with numerous biotechnology and pharmaceutical companies developing cell-based treatments.
Similar companies
Latest newsMore news →
MaxCyte, Inc. launched the CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays, available through its SeQure™ service, to improve off-target assessment for genome editing therapies.16d agoMaxCyte reported total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue.23d ago